VacZine Analytics  
MarketVIEW: Herpes Simplex Virus (TX) vaccines

Published: April 2024

Herpes Simplex Virus (HSV-1/2) are ubiquitous members of the human herpes family and are transmitted by oral/genital contact. Both viruses cause lifelong oral/ocular and/or genital infections (GUD). Although most individuals infected with HSV-1/2 have minimal signs of infection, persons with GUD can experience frequent disease reactivation which have a considerable impact on sexual reproductive health and wellbeing. Neonatal herpes, although rare, can have devastating consequences for the new-born infant with a mortality rate of ~60-85%. The WHO has estimated that 491m persons in 2016 were living with HSV-2 globally (15-49 yrs) which is 13.2% prevalence in this age group. HSV-1 is estimated to infect 3.7 bn people worldwide. HSV-2 is also a significant contributor to global HIV incidence especially in low-income countries.

Antiviral treatments e.g., acyclovir/valacyclovir do exist for HSV infections and are designed to prevent symptomatic disease, improve quality of life and suppress the virus to prevent transmission to sexual partners. A HSV-2 therapeutic vaccine that can suppress symptomatic disease and prevent transmission could have great utility in infected populations and bring benefits via more convenient administration profile/long-lived protection. With new mRNA-focused vaccine competitors such as ModernaTX and BioNTECH now involved with HSV vaccines e.g., mRNA-1608 and BNT-163 (prophylactic), a renewed interest in therapeutic vaccine development is expected. GSK have also a new therapeutic approach, GSK3943104A after terminating a SAM candidate, GSK4108771A indicating their committment to the field. Other competitors include Eurocrine, Rational Vaccines and Simplexia.

This MarketVIEW product is a comprehensive Executive Presentation (~175 slides, .pdf) and interactive MS-Excel forecast model which investigate the scenario-based interplay and commercial potential of HSV therapeutic vaccines across key target groups in 20 nations (public/private) including North America, Europe, Australia and Japan A thorough review of latest epidemiological/impact studies is presented along with discussion of vaccinology/new R&D strategies with a focus on next generation concepts. A competitor landscape is also provided with examination of the merits of mRNA approaches. Recently, the analysis includes expert viewpoints from the latest CDC/NIAID Joint Workshop on Herpes which was held 4th-5th November 2022.

THIS PRODUCT IS A SUMMARY PRESENTATION (~180 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): Prince Akachi, Mateus Campos Felipe (@unsplash license)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV038 Click here>> CONTACT US

*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2022 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains